Related Experiment Videos
MDM2 gene amplification in metastatic osteosarcoma
1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Abstract:
The human homologue of the murine double minute 2 gene (MDM2), a p53-binding protein which may act as a regulator of p53 protein function, has recently been cloned. Initial studies of this gene in a variety of human tumors have shown frequent gene amplification in most types of sarcomas, including osteosarcomas. Amplification of the MDM2 gene may produce a functional inactivation of the p53 protein. To examine possible clinical or pathological correlates of MDM2 gene amplification in osteosarcoma, we studied 28 specimens on 26 patients with high grade osteosarcoma (16 primary, 11 metastatic, and 1 local recurrence) for MDM2 gene amplification by Southern blot analysis, using two MDM2 complementary DNA probes isolated by polymerase chain reaction. Four specimens (14%) showed amplification, including 3 metastases and 1 local recurrence. None of the primary osteosarcoma specimens had detectable MDM2 gene amplification. None of the specimens tested showed MDM2 gene rearrangement. In the present series, MDM2 gene amplification was detected significantly more frequently in metastatic or recurrent osteosarcomas than it was in primary osteosarcomas (P = 0.02). Our data suggest that MDM2 gene amplification may be associated with tumor progression and metastasis in osteosarcoma. Further investigation is warranted on the potential clinicopathological correlates of MDM2 gene amplification in osteosarcoma.
Insights
MDM2 gene amplification is linked to osteosarcoma progression. This amplification was found more often in metastatic or recurrent tumors than in primary ones, suggesting a role in tumor spread.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MDM2 gene, a regulator of p53 protein function, is frequently amplified in sarcomas.
- MDM2 gene amplification may lead to functional inactivation of the p53 protein, a crucial tumor suppressor.
- Osteosarcoma is a high-grade bone cancer where MDM2 amplification is being investigated.
Purpose of the Study:
- To investigate the clinical and pathological correlations of MDM2 gene amplification in high-grade osteosarcoma.
- To determine if MDM2 gene amplification is associated with tumor progression and metastasis in osteosarcoma.
Main Methods:
- Southern blot analysis was used to detect MDM2 gene amplification in 28 osteosarcoma specimens from 26 patients.
- Polymerase chain reaction (PCR) was employed to isolate MDM2 complementary DNA probes for the analysis.
- Specimens included primary, metastatic, and locally recurrent high-grade osteosarcomas.
Main Results:
- MDM2 gene amplification was detected in 14% (4/28) of the osteosarcoma specimens.
- Amplification was observed in 3 metastatic and 1 local recurrence specimen; none were found in primary osteosarcomas.
- MDM2 gene amplification was significantly more frequent in metastatic or recurrent osteosarcomas compared to primary ones (P = 0.02).
Conclusions:
- MDM2 gene amplification is associated with tumor progression and metastasis in osteosarcoma.
- The findings suggest MDM2 amplification may play a role in the aggressiveness of osteosarcoma.
- Further research is needed to explore the clinicopathological significance of MDM2 gene amplification in osteosarcoma.